Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Godaddy Inc (GDDY) vs 10X Genomics Inc (TXG) Price & Performance

Godaddy IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Godaddy Inc vs 10X Genomics Inc — how do they compare? Godaddy Inc trades at $93 (market cap $12.09B), while 10X Genomics Inc trades at $43.48 (market cap $5.81B). The key difference: Godaddy Inc is far larger — about 2.1× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.

GDDYTXG
Market Cap
$12.09B$5.81B
Sector
TechnologyHealth
52-Week High
$169.40$45.80
52-Week Low
$75.07$11.34
Enterprise Value
$14.67B$5.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Godaddy Inc

GoDaddy (GDDY) trades at $91.10, showing modest daily gains. The stock presents a mixed picture: strong technical indicators signal a bullish trend, while fundamentals reveal robust profitability and consistent earnings beats. However, a high P/B ratio and ongoing securities litigation investigations introduce notable risks. The company continues to innovate, recently launching an AI-powered developer platform to expand its service ecosystem.

The outlook is cautiously optimistic. A significant analyst consensus price target of $123 suggests substantial upside potential, supported by strong cash flow and share buybacks. Primary risks include the high valuation on book value, legal overhang from shareholder investigations, and potential revenue growth deceleration. The stock's investment case hinges on execution of its AI initiatives and maintaining its margin profile.

10X Genomics Inc

TXG is trading at $45.80, up 9.65% today, showing strong momentum despite mixed analyst sentiment. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company continues to report revenue growth with improving margins, narrowing losses from -$166M in 2022 to -$44M in 2025. Recent developments include strategic acquisitions and research collaborations that strengthen its life sciences technology position.

The outlook remains cautiously optimistic as TXG demonstrates operational improvement and strategic positioning in genomics technology. Key opportunities include continued margin expansion and platform adoption, while risks involve persistent profitability challenges and competitive pressures. Analyst consensus shows divided opinions with a $37.71 price target below current levels, suggesting potential near-term volatility despite long-term growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Godaddy Inc

GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.

Read more on GDDY

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG